Evotec SE announced that the U.S. Department of Defense (DOD) awarded its Seattle, WA-based subsidiary, Just – Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (mAbs) for use in the development of a treatment and/or prophylaxis for COVID-19.   The DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) is executing this effort in coordination with the Office of the Assistant Secre...